Optimi Health Corp. announces that it has been selected to manufacture and supply MDMA for a practitioner experiential clinical trial, sponsored by Numinus Wellness Inc. (“Numinus”), announced earlier June 15, 2023. This clinical trial will provide practitioners training to provide MDMA-assisted therapy with the opportunity to participate in experiential training – through a training partnership between Numinus and the Multidisciplinary Association for Psychedelic.

The clinical trial application has been submitted by Numinus through its wholly owned subsidiary Numinus Wellness Research Inc. If approved by Health Canada, the clinical trial would enable practitioners interested in MDMA-assisted therapy the ability to experience and observe MDMA sessions to further their understanding of psychedelic-assisted therapy and allow Numinus to test the safety and efficacy of MDMA in healthy subjects.